Conference abstractPublished 7 Sep 2016
Targeting the nuclear translocation of MAPKs as a novel anti-inflammatory and anti-cancer therapy
Weizmann Institute of Science, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A hallmark of MAPK signaling is their nuclear translocation upon stimulation, which is necessary for their physiological/ pathological functions. We have identified two novel, distinct, regulated nuclear translocation mechanisms for ERK1/2 and JNK/ p38, of which we made use of as a promising therapeutic approach. We developed a myristoylated, NTS-derived phosphomimetic peptide (EPE peptide), which blocked ERK1/2 nuclear translocation by inhibiting its interaction with importin7 (Imp7). In culture, we showed that the EPE peptide induced apoptosis of melanoma cells, inhibited the proliferation of other cancer cells but had no effect on immortalized cells. In xenograft models, the peptide was significantly more effective than PLX4032, a selective potent BRAF inhibitor, in preventing tumor recurrence of treatment-eradicated melanoma xenografts. We also developed additional p38-derived myristoylated peptide, termed PERY peptide, which prevented JNK1/2 and p38Ã?±/Ã?² nuclear translocation. When tested in a model of inflammation associated DSS-induced acute colitis, the PERY peptide significantly reduced inflammation and intestinal damage. Using the model of a combined single dose of the carcinogen AOM with repetitive cycles of DSS in order to induce tumorigenesis, we showed that systemic treatment with the PERY peptide significantly prevented colon cancer. Treatment with the PERY peptide significantly reduced tumor load and maintained healthier colon histology, even better than colon of mice treated with the commercial p38 MAPK inhibitor, SB203580. Both the cancer and inflammatory models support the use of nuclear translocation of MAPKs as a novel drug target for signaling related diseases.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Rony Seger”